EVER001 (previously known as XNW1011) is a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in development globally for the treatment of renal diseases. BTK is an essential ...
Webcast Link: https://www.acecamptech.com/meeting_live/70512679/774680?event_id=60510700 EVER001 (previously known as XNW1011) is a next-generation covalent ...
Glomerulonephritides vary in presentation and can cause fluid overload, hypertension, and kidney failure. They are either primary (intrinsic to the kidney), such as minimal change disease or ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with ...